VBI Vaccines Inc VBIV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VBIV is a good fit for your portfolio.
News
-
VBI Vaccines Reports Full Year 2023 Financial Results
-
VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
-
VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma
-
VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform
-
Thinking about buying stock in Arena Group, Dunxin Financial Holdings, Nano-X Imaging, VBI Vaccines, or SuRo Capital?
-
VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences
-
VBI Vaccines to focus on hep B treatments, conduct 1-for-30 reverse stock split
Trading Information
- Previous Close Price
- $0.61
- Day Range
- $0.58–0.61
- 52-Week Range
- $0.45–3.47
- Bid/Ask
- $0.59 / $0.59
- Market Cap
- $16.78 Mil
- Volume/Avg
- 130,138 / 491,177
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.15
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
VBI Vaccines Inc is a commercial-stage, the biopharmaceutical company which is engaged in developing next-generation vaccines to address unmet needs in infectious disease and immuno-oncology. The company manufactures Sci-B-Vac product which is a hepatitis B (HBV) vaccine for adults, children, and newborns. Its products include Virus-Like Particle which is vaccine platform which allows for the design of enveloped virus-like particle vaccines that closely mimic the target viruses. The company operates through the single segment being Developing vaccines to address unmet needs in infectious disease and immuno-oncology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 138
- Website
- https://www.vbivaccines.com
Valuation
|
Metric
|
VBIV
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.03 |
Price/Sales | 1.15 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
VBIV
|
|---|---|
Quick Ratio | 0.33 |
Current Ratio | 0.48 |
Interest Coverage | −10.72 |
Quick Ratio
VBIV
Profitability
|
Metric
|
VBIV
|
|---|---|
Return on Assets (Normalized) | −27.13% |
Return on Equity (Normalized) | −104.47% |
Return on Invested Capital (Normalized) | −29.35% |
Return on Assets
VBIV
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Qbsrskqn | Fhdgk | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Dlhqwnlf | Fzgltw | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Wlpdcrwy | Fmdgz | $99.5 Bil | |
MRNA
| Moderna Inc | Qghtgzgvt | Tjr | $38.8 Bil | |
ARGX
| argenx SE ADR | Cxxpkzqr | Dzg | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Vxkqgxmsw | Xtk | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Rxglkmj | Pshbzt | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vwcvhghs | Wnkjwf | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Gmyqhdhhd | Lknds | $12.5 Bil | |
INCY
| Incyte Corp | Jdhpglrc | Ymtzlb | $11.6 Bil |